Fidelity Investments’s ClearPoint Neuro CLPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$169K Buy
9,501
+1,329
+16% +$16.6K ﹤0.01% 3743
2026
Q1
$74.4K Buy
8,172
+253
+3% +$3.19K ﹤0.01% 3937
2025
Q4
$108K Buy
7,919
+310
+4% +$5.75K ﹤0.01% 3719
2025
Q3
$166K Sell
7,609
-326
-4% -$3.84K ﹤0.01% 3446
2025
Q2
$94.7K Buy
7,935
+536
+7% +$6.75K ﹤0.01% 3628
2025
Q1
$88K Sell
7,399
-185
-2% -$2.88K ﹤0.01% 3614
2024
Q4
$117K Buy
7,584
+11
+0.1% +$142 ﹤0.01% 3480
2024
Q3
$84.9K Sell
7,573
-43
-0.6% -$412 ﹤0.01% 3549
2024
Q2
$41K Sell
7,616
-92
-1% -$532 ﹤0.01% 3716
2024
Q1
$52.4K Buy
7,708
+2
+0% +$14 ﹤0.01% 3562
2023
Q4
$52.3K Buy
7,706
+3,476
+82% +$19.7K ﹤0.01% 3494
2023
Q3
$21.2K Buy
4,230
+3,930
+1,310% +$23.4K ﹤0.01% 3779
2023
Q2
$2.17K Sell
300
-1,947
-87% -$16.6K ﹤0.01% 4568
2023
Q1
$19K Buy
2,247
+1,070
+91% +$9.37K ﹤0.01% 3861
2022
Q4
$9.97K Sell
1,177
-412
-26% -$3.9K ﹤0.01% 4016
2022
Q3
$16K Sell
1,589
-95
-6% -$1.25K ﹤0.01% 3926
2022
Q2
$22K Buy
1,684
+979
+139% +$10K ﹤0.01% 3837
2022
Q1
$7K Buy
+705
New +$6.42K ﹤0.01% 4325

Other funds holding CLPT

Fidelity Investments's CLPT Position: Q2 2026 in Review

Fidelity Investments increased its ClearPoint Neuro (CLPT) stake by 16% in Q2 2026, buying an estimated $16.6K and bringing the position to 9,501 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #3743.

Fidelity Investments first reported a position in CLPT in Q1 2022 and has held it in 18 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Fidelity Investments held 9,501 shares of ClearPoint Neuro worth $169K as of Q2 2026.
  • Fidelity Investments bought 1,329 ClearPoint Neuro shares in Q2 2026, an estimated $16.6K.
  • ClearPoint Neuro made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3743 holding.
  • Fidelity Investments first reported a position in ClearPoint Neuro in Q1 2022 and has held it in 18 quarters since.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.